Joshua Burke, MS

Long-Term Safety and Tolerability of Once-Daily Valbenazine in Patients With Tardive Dyskinesia

Objective: To evaluate the long-term safety and tolerability of once-daily valbenazine in adults with tardive dyskinesia (TD).

Dan Michel , PharmD;

Joshua Burke , MS;

Scott Siegert , PharmD;

Khodayar Farahmand , PharmD;

Martha Sajatovic , MD;

Stephen Marder , MD;

03/01/2019

Effects of Concomitant Medication Use on Tardive Dyskinesia Outcomes in Long-Term Valbenazine Trials

Background: Patients with tardive dyskinesia (TD) often take multiple concomitant medications for psychiatric comorbidities. Data from long-term valbenazine trials were analyzed to evalua...

Richard Josiassen , PhD;

Leslie Lundt , MD;

Andrew J. Cutler , MD;

Khodayar Farahmand , PharmD;

John Kane , MD;

Joshua Burke , MS;

Scott Siegert , PharmD;

03/01/2019

Effects of Long-Term Valbenazine on Psychiatric Status in Patients With Tardive Dyskinesia and a Primary Mood Disorder

Objective: In two long-term phase 3 studies, sustained TD improvements were observed in participants who received once-daily treatment with valbenazine (40 or 80 mg). Data from these stud...

Joshua Burke , MS;

Scott Siegert , PharmD;

Gary Remington , MD, PhD;

Rachel Weber , PhD;

Leslie Lundt , MD;

Khodayar Farahmand , PharmD;

Christoph U. Correll , MD;

Roger McIntyre , MD, FRCPC;

03/01/2019